102 related articles for article (PubMed ID: 25261297)
1. Anti- or pro-proliferation—conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.
Ekblad L; Welinder C; Kjellén E; Brun E; Wennerberg J
Oral Oncol; 2015 Jan; 51(1):46-52. PubMed ID: 25261297
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
[TBL] [Abstract][Full Text] [Related]
3. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
[TBL] [Abstract][Full Text] [Related]
4. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
5. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
6. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
7. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
Grandis JR; Chakraborty A; Zeng Q; Melhem MF; Tweardy DJ
J Cell Biochem; 1998 Apr; 69(1):55-62. PubMed ID: 9513046
[TBL] [Abstract][Full Text] [Related]
8. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ
Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377
[TBL] [Abstract][Full Text] [Related]
11. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.
Barnea I; Ben-Yosef R; Karaush V; Benhar I; Vexler A
Head Neck; 2013 Aug; 35(8):1171-7. PubMed ID: 22965815
[TBL] [Abstract][Full Text] [Related]
14. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; Ackermann H; May A; Knecht R; Hambek M
Anticancer Res; 2008; 28(4B):2239-43. PubMed ID: 18751401
[TBL] [Abstract][Full Text] [Related]
15. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
16. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
Zhang Q; Thomas SM; Xi S; Smithgall TE; Siegfried JM; Kamens J; Gooding WE; Grandis JR
Cancer Res; 2004 Sep; 64(17):6166-73. PubMed ID: 15342401
[TBL] [Abstract][Full Text] [Related]
17. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells.
Lango M; Wentzel AL; Song JI; Xi S; Johnson DE; Lamph WW; Miller L; Grandis JR
Clin Cancer Res; 2003 Sep; 9(11):4205-13. PubMed ID: 14519647
[TBL] [Abstract][Full Text] [Related]
18. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
19. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma.
Rubin Grandis J; Tweardy DJ; Melhem MF
Clin Cancer Res; 1998 Jan; 4(1):13-20. PubMed ID: 9516947
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
